Throughout my career, I’ve witnessed sepsis devastate countless patients and families, including my own — my father died from immune dysregulation on top of sepsis. This tragic loss ignited a personal mission to combat inflammatory conditions.
Sepsis strikes without warning, claiming a life every 2.8 seconds. It imposes a staggering $62 billion annual burden on the U.S. healthcare system. Despite its devastating impact, it remains largely overlooked in public health discussions.
This silent killer turns routine infections into catastrophic bodily responses, leading to rapid organ failure and death. Current treatments only manage symptoms, neglecting the root cause of sepsis. There has not been an effective therapy targeting the underlying inflammatory process—until now.
My experience with sepsis has led to the creation of XGal-3®, a groundbreaking new device designed to halt sepsis progression by targeting Galectin-3, a protein driving the deadly inflammatory process. I have researched Galectin-3 extensively and have discovered that blocking the overproduction of this protein is the key to halting inflammation and preventing fibrosis (excessive and irreversible scarring and thickening of tissues in organs).
When sepsis strikes, every second counts. Yet, current treatments require a complex, time-consuming protocol that can take hours to implement, while severe cases can become fatal within 12 hours. XGal-3® XGal-3® offers the potential for earlier, faster intervention, addressing the root cause and helping doctors respond quickly when it matters most.
Targeting the Key Driver of Sepsis
Galectin-3 is a key driver of sepsis when released into the bloodstream. During sepsis and acute kidney injury (AKI), this protein triggers a cascade of harmful effects, including:
- Inflammation
- Disease progression
- Organ fibrosis
- Increased morbidity and mortality
Diseases Associated with Galectin-3:
- Sepsis
- Kidney diseases (AKI, CKD)
- Heart disease
- Liver cirrhosis
- Cancer
- Pulmonary hypertension
- Stroke
- Diabetes
- Autoimmune diseases
- Neuroinflammatory diseases
XGal-3® Brings New Hope for Sepsis Patients
XGal-3® is a novel medical device that works like dialysis but with a crucial difference. It combines therapeutic apheresis (a well-established procedure) with targeted removal of Galectin-3. Using proprietary anti-Galectin-3 ligand traps, the device selectively eliminates this key inflammatory protein from the bloodstream, potentially halting sepsis progression.
By disrupting the pathological process early, XGal-3® aims to prevent the devastating sequence of inflammation and organ damage, helping to save lives. This targeted strategy addresses the root cause of sepsis, providing a breakthrough solution and new hope for millions.
The technology has shown remarkable results in our research. In large animal studies, XGal-3® rapidly demonstrated the incredible ability to halt the devastating cascade of sepsis in hours, an achievement that no currently approved treatment has been able to accomplish. It’s also important to note that no adverse side effects were observed with the use of XGal-3®.
Our patented technology, supported by two NIH grants and protected by over 60 patents across 34 countries, has the potential to transform the treatment of sepsis and other inflammatory and fibrotic diseases such as acute kidney injury (AKI), chronic kidney disease (CKD), heart failure, liver fibrosis, and cancer. With a world-class team, we’ve developed a working prototype and are rapidly advancing toward clinical trials.
Breakthrough Device Designation Granted to XGal-3®
The FDA has awarded XGal-3® its Breakthrough Device Designation, a highly coveted label in the medical world that validates technologies tackling urgent, unmet medical needs. It gives patients timely access to innovative treatments that are highly vetted for safety and effectiveness. And often, it offers hope where there is none.
I’m honored to share that I was recently featured in an exclusive interview about XGal-3® with KingsCrowd, considered the “Bloomberg of Equity Crowdfunding” for helping identify the most promising high-tech investment opportunities in private markets.
Read the Feature on KingsCrowd
In this in-depth article, I share insights into XGal-3’s® Breakthrough Device Designation from the FDA and discuss how this remarkable technology could transform sepsis treatment. I also get into details such as the $62B market opportunity my company, Eliaz Therapeutics, is pursuing and our clinical development timeline.
This independent coverage from KingsCrowd’s expert analysts provides strong validation of our progress and potential. Read the full interview above!
I’ve dedicated my career to integrating ancient healing wisdom with modern medical science. By merging the holistic perspective of integrative medicine with cutting-edge technology, my team and I have been able to explore new frontiers in critical care. This approach extends beyond just addressing the symptoms, but the root cause of sepsis and other devastating inflammatory conditions, potentially saving millions of lives.
Resources for Patients, Caregivers, and Doctors
• For More Information About XGal-3®, visit EliazTherapeutics.com.
• KingsCrowd Q&A Interview with Dr. Eliaz About Sepsis and XGal-3®: https://www.youtube.com/watch?v=s4iGtYyVfcc
• “What Investors Want to Know: Eliaz Therapeutics is Taking on Sepsis With a First-in-Class Apheresis Device”— Interview with Dr. Eliaz about XGal-3®.
References
Sepsis statistics: Global Sepsis Alliance and World Sepsis Day
Rudd KE, Johnson SC, Agesa KM, et al. Global, regional, and national sepsis incidence and mortality, 1990-2017: analysis for the Global Burden of Disease Study. Lancet. 2020 Jan 18;395(10219):200-211. doi: 10.1016/S0140-6736(19)32989-7. PMID: 31954465; PMCID: PMC6970225.
